Income statement, balance sheet and cash flow statement for the last 7 fiscal years, taken from the XBRL data Kymera Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
2.93
34
72.8
46.8
78.6
47.1
39.2
Cost of revenue
46.8
78.6
47.1
39.2
Gross profit
0
0
0
0
Research and development
37.2
62.1
137
164
189
240
317
General and administrative
7.98
18.2
36.3
43.8
55
63.5
68.2
Operating expenses
45.1
80.3
173
208
244
309
389
Operating income
-42.2
-46.3
-101
-161
-166
-262
-349
Interest income
6.62
18.8
38
38.4
Other non-operating income
0.96
0.71
0.31
6.45
18.6
37.8
38
Pre-tax income
-311
Income tax
0
0
0
0
0
Net income
-41.2
-45.6
-100
-155
-147
-224
-311
EBITDA
-41.4
-44.5
-98.1
-158
-162
-254
-341
EPS, basic
-24.28
-3.15
-2.09
-2.87
-2.52
-2.98
-3.69
EPS, diluted
-24.28
-3.15
-2.09
-2.87
-2.52
-2.98
-3.69
Shares, basic (weighted)
1.7
17.3
48
53.9
58.4
75
84.5
Shares, diluted (weighted)
1.7
17.3
48
53.9
58.4
75
84.5
Balance sheet
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
76
31
48
68.4
110
120
357
Short-term investments
15.9
265
394
339
265
368
491
Receivables
0
15
0
0
Other current assets
0.89
4.7
8.72
9.71
11.7
21.5
22.9
Total current assets
92.8
302
451
419
405
510
871
Property, plant and equipment
3.79
10.8
11.9
13.3
48.1
50.5
43.2
Lease right-of-use assets
18.3
9.85
9.43
8.91
52.9
47.4
42.4
Long-term investments
163
125
152
61.4
362
771
Other non-current assets
1.77
0.03
2.02
3.02
2.12
1.95
9.11
Total assets
117
487
606
603
576
978
1,743
Accounts payable
3.28
4.37
4.01
4.34
7.08
5.99
4.02
Accrued liabilities
4.57
10.3
23
27.5
33.9
34.9
42.3
Deferred revenue
23.3
92.6
61.7
35.3
37.9
13.6
22.9
Total current liabilities
34.6
111
92.5
71.3
85.7
67.8
83.2
Lease liabilities
16.7
14.1
13.2
12.1
77
72.4
67
Other non-current liabilities
0.1
0.07
0.25
0
0
Total liabilities
82
203
146
113
181
142
163
Paid-in capital
2.04
413
689
879
926
1,592
2,644
Retained earnings
-76.5
-129
-229
-384
-531
-755
-1,066
Other comprehensive income
0.01
-0.13
-0.66
-4.95
-0.55
-1.49
1.8
Shareholders' equity
-74.4
284
460
490
395
836
1,580
Total equity
-74.4
284
460
490
395
836
1,580
Total liabilities and equity
117
487
606
603
576
978
1,743
Shares outstanding
1.93
44.5
51.5
55
55.6
64.9
81.3
Cash flow statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-41.2
-45.6
-100
-155
-147
-224
-311
Depreciation and amortization
0.83
1.76
2.4
2.98
3.57
7.37
8.31
Stock-based compensation
1.2
5.19
25
35.5
43.1
55
59.9
Change in payables
0.9
0.99
0.05
0.25
2.04
-0.31
-1.97
Cash from operations
17.9
88.1
-129
-153
-103
-195
-233
Capital expenditures
-0.53
-9.1
-1.6
-2.84
-34.5
-12.8
-1.45
Purchases of investments
-16
-529
-456
-446
-189
-901
-1,008
Sales and maturities of investments
116
358
469
364
510
488
Cash from investing
-16.5
-423
-99.8
20.5
140
-404
-521
Stock issued
0.07
0.16
7.63
0
0
48.7
0
Cash from financing
34.9
289
250
153
4.19
609
991
Net change in cash
36.3
-45.2
21.5
20.4
41.3
10.3
237
Free cash flow
17.4
79
-131
-156
-137
-207
-234
Interest paid
0.05
0.12
0.16
0.18
0.16
0.21
0.31
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $111.95 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
0.0%
Gross profit / revenue.
Operating margin
-333.5%
Operating income / revenue.
EBITDA margin
-326.1%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-285.3%
Net income / revenue.
FCF margin
-226.6%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-225.5%
Cash from operations / revenue.
Return on equity (ROE)
-19.9%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-18.2%
Net income / average total assets.
Return on invested capital (ROIC)
-20.0%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
357.7%
Research and development expense / revenue.
Stock-based pay / revenue
62.1%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
1.1%
Capital expenditures / revenue.
D&A / revenue
7.4%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-16.7%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-5.7%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
2.9%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
89.0%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
47.7%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
41.0%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
78.2%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
42.4%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
29.0%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
12.6%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
16.1%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
37.2%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
10.3x
Current assets / current liabilities.
Quick ratio
9.97x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
9.69x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$1.07
Revenue / diluted weighted shares.
FCF per share
-$2.42
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$2.41
Cash from operations / diluted weighted shares.
Book value per share
$18.23
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
88.7x
Market cap / revenue.
P/B
6.17x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
6.17x
Market cap / tangible book value, when positive.
EV/Sales
82.1x
Enterprise value / revenue.
FCF yield
-2.6%
Free cash flow / market cap.
Earnings yield
-3.2%
Net income / market cap (the inverse of P/E).
What was Kymera Therapeutics, Inc.'s revenue in fiscal 2025?
Kymera Therapeutics, Inc. reported revenue of $39.2M for fiscal 2025, 16.7% lower than the year before.
Was Kymera Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $311.4M.
How much free cash flow did Kymera Therapeutics, Inc. generate in fiscal 2025?
Cash from operations of $232.9M minus capital expenditures of $1.4M left free cash flow of -$234.3M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.